LCL-161
-
LCL-161
structure -
-
CAS No:
1005342-46-0
-
Formula:
C26H33FN4O3S
-
Chemical Name:
LCL-161
-
Synonyms:
LCL-161;N-[(1S)-1-Cyclohexyl-2-{(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]-1-pyrrolidinyl}-2-oxoethyl]-N2-MethylalaninaMide;(2S)-N-[(1S)-1-Cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-2-thiazolyl]-1-pyrrolidinyl]-2-oxoethyl]-2-(methylamino)-propanamide;N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-2-thiazolyl]-1-pyrrolidinyl]-2-oxoethyl]-2-(methylamino)-(2S)-propanamide;(2S)-N-[(1S)-1-Cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-2-thiazolyl]-1-pyrrolidinyl]-2-oxoethyl]-2-(methylamino)-propanamide LCL 161;(S)-N-((S)-1-Cyclohexyl-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)
- Categories:
-
CAS No:
Description
LCL161 has been used in trials studying the treatment of Leukemia, Neoplasms, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others.
Characteristics
120
4.3
Off-white to yellow solid
1.245±0.06 g/cm3(Predicted)
713.7±60.0 °C(Predicted)
Safety Information
3077
P264, P270, P301+P312, P330, P501
H302
|Warning|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P264, P270, P301+P312, P330, and P501|The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
LCL-161 Use and Manufacturing
B6 to B7 (Compound (I))Charge a 2 L Argonaut reactor with 12O g (20 mmol) of crude B6 in 360.8 g (400 mL) of ethyl acetate. Heat the solution to 45 +/- 3B6 to B7 (Compound (I))Charge a 2 L Argonaut reactor with 12O g (20 mmol) of crude B6 in 360.8 g (400 mL) of ethyl acetate. Heat the solution to 45 +/- 30C , slowly add 109.1 g (120 mL) of HCI (5-6 N) in isopropyl alcohol while maintainingtemperature at 45 +/- 30C over 30 min. Stir and hold at 45 +/- 3 0C for 2 h. Take a sample for Process Steering Control. If PSC passes, cool the reaction mixture to 18 +/- 3 0C. Slowly add this solution to a 2 L Argonaut reactor containing 82.9 g of potassium carbonate in 500 g of water while maintaining the temperature at 5 +/- 30C. Stir at 5 +/- 3C for 30 min, add 451 g (500 mL )of ethyl acetate. Warm the solution to 20 +/- 3C and hold at this temperature for 1 h. Separate the two layers. Keep the top layer since B7 is in this organic phase. Wash the organic layer with 286.6 g (250 mL) of brine. Separate the bottom layer (aqueous).Concentrate the top organic layer to 500 mL under vacuum at 300C. Slowly add 1368 g (2 L) of heptanes while maintaining the temperature at 30 +/- 3 0C. Cool the suspension to 18 +/- 3 0C and hold at 18 +/- 3 0C for 1 h. Filter the solids and wash the solids with 136 g ( 200 mL) of heptanes containing octastat. Dry the solids in an oven at 45 0C for 16 h to give 80 g of B7 in 80% yield.The preferred compounds are selected from the group consisting of: (S)-N-((S)-1-Cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide; (S)-N-[(S)-Cyclohexyl-(ethyl-{(S)-1-[5-(4-fluoro-benzoyl)-pyridin-3-yl]-propyl}carbamoyl)-methyl]-2-methylamino-propionamide; (S)-N-((S)-1-Cyclohexyl-2-{(S)-2-[5-(4-fluoro-phenoxy)-pyridin-3-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide; and N-[1-Cyclohexyl-2-(2-{2-[(4-fluorophenyl)-methyl-amino]-pyridin-4-yl}pyrrolidin-1-yl)-2-oxo-ethyl]-2-methylamino-propinamide;
Computed Properties
Molecular Weight:500.6
XLogP3:4.3
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:8
Exact Mass:500.22574026
Monoisotopic Mass:500.22574026
Topological Polar Surface Area:120
Heavy Atom Count:35
Complexity:757
Defined Atom Stereocenter Count:3
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Recommended Suppliers of LCL-161
-
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives
Latest News on LCL-161
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
Dabrafenib
1195765-45-7
-
BOC-VAL-VAL-OH
69209-73-0
-
BMS 303141
943962-47-8
-
(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide Formula
60117-17-1
-
(2S)-2-acetamido-6-amino-N-[(2S)-2-amino-3-methylbutanoyl]-N-propylhexanamide Formula
57899-96-4
-
1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Formula
26130-02-9
-
L-Tyrosyl-L-phenylalanine Structure
17355-11-2
-
C-REACTIVE PROTEIN FRAGMENT 77-82 Structure
130349-01-8
-
What is Sildenafil
139755-83-2
-
What is Dacomitinib
1110813-31-4